Soligenix公司近日宣布,其研发药物SGX945已获得欧盟委员会颁发的孤儿药资格认定,适应症为白塞病。该认定将加速SGX945在欧洲的临床开发与审批进程,为患者提供新的治疗希望。
Soligenix公司近日宣布,其研发药物SGX945已获得欧盟委员会颁发的孤儿药资格认定,适应症为白塞病。该认定将加速SGX945在欧洲的临床开发与审批进程,为患者提供新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.